Global Companion Diagnostics Partnership Agreements and Contract Terms and Agreements Analysis Report 2010-2021

DUBLIN, December 17, 2021– (BUSINESS WIRE) – The report “Global Companion Diagnostics 2010-2021 Partnership Terms and Agreements” has been added to offer.

The Global Companion Diagnostics Partnering Terms and Agreements 2010-2021 report provides full access to available offerings and contract documents for over 500 Companion Diagnostics offerings.

The report provides detailed understanding and analysis of how and why companies enter into partnership agreements with Companion Diagnostics. These agreements tend to be multi-component, starting with collaborative R&D, and moving on to the commercialization of the results.

This report details the latest Companion Diagnostics agreements announced in Life Sciences since 2010.

The report presents the reader with a comprehensive examination of Companion Diagnostics’ agreement trends, key players, major agreement values, and agreement financial data, providing an understanding of how, why, and under what terms, companies enter into deals. partnership with Companion Diagnostics.

The report presents financial agreement terms values ​​for Companion Diagnostics agreements, listing by aggregate value, upfront payments, milestone payments, and royalties, allowing readers to analyze and compare the financial value of agreements.

The central section of the report explores the main negotiators in the area of ​​Companion Diagnostics partnerships; The values ​​of the most important transactions and the most active Companion Diagnostics trading companies are reported, allowing the reader to see who is successful in this dynamic trading marketplace.

One of the highlights of the report is that over 500 Companion Diagnostics’ online deal files of actual dealings, as disclosed by the parties to the deal, are included towards the end of the report in a formatted format. directory – by AZ company, stage of development, type agreement, therapeutic orientation and type of technology – it’s easy to reference. Each transaction record in the report is linked via a web link to an online version of the transaction.

Additionally, when available, records include contractual documents as submitted to the Securities Exchange Commission by the companies and their partners. While many companies will be looking for details on payment terms, the devil is in the details of how payments are triggered – contract documents provide that insight where press releases and databases don’t. do not.

Key Benefits

  • In-depth understanding of Companion Diagnostics transaction trends since 2010

  • Access to title, advance, milestone and royalty data

  • Detailed access to current Companion Diagnostics contracts with leading biopharmaceutical companies

  • Identify the most active Companion Diagnostics dealmakers since 2010

  • Overview of terms included in a Companion Diagnostics partnership agreement, with concrete examples

  • Understand the key terms of agreements that companies have agreed to in previous agreements

  • Undertake due diligence to assess the adequacy of the terms of your proposed agreement for partner companies

Companion Diagnostics Partnership Terms and Agreements include:

  • Companion Diagnostics Transaction Trends in the Biopharmaceutical Industry since 2010

  • Analysis of the transaction structure of Companion Diagnostics

  • Access to title, advance, milestone and royalty data

  • Access to Companion Diagnostics contractual documents

  • Main Companion Diagnostics transactions in value since 2010

  • The most active Companion Diagnostics traders since 2010

In the terms and partnership agreements of Global Companion Diagnostics 2010-2021, the available offers are listed by:

Main topics covered:


Chapter 1 Introduction

Chapter 2 – Trends in Trading Companion Diagnostics

2.1. introduction

2.2. Companion Diagnostics’ partnership over the years

2.3. The most active Companion Diagnostics traders

2.4. Companion Diagnostics Partnership by Transaction Type

2.5. Companion Diagnostics partnership by therapeutic area

2.6. Terms of the Companion Diagnostics Partnership Agreement

2.6.1 Key values ​​of the Companion Diagnostics partnership

2.6.2 Companion Diagnostics processes upfront payments

2.6.3 Companion Diagnostics processes milestone payments

2.6.4 Companion Diagnostics Royalty Rate

Chapter 3 – Leading Companion Diagnostic Offerings

3.1. introduction

3.2. Top Companion Diagnostics Deals By Value

Chapter 4 – The Most Active Companion Diagnostics Traders

4.1. introduction

4.2. The most active Companion Diagnostics traders

4.3. Most Active Companion Diagnostics Partner Company Profiles

Chapter 5 – Companion Diagnostics Contract Negotiation Directory

5.1. introduction

5.2. Companion Diagnostics Contract Directory

Chapter 6 – Companion Diagnostics dealmaking by technology type

Chapter 7 – Partner Resource Center

7.1. Online partnership

7.2. Partnership events

7.3. Further reading on negotiation

Companies mentioned

  • Max Planck Institute for Infection Biology

  • Nicholas Conor Institute for Pediatric Cancer Research

  • Astellas Pharma

  • Astellas Pharma United States

  • Development of translational drugs

  • IncellDx

  • Seattle genetics

  • The Fleury Group

  • Singulex

  • WAVE Life Sciences

  • RedHill Biopharma

  • Cornell University

  • HistologyX

  • Cephalon

  • T2 solutions

  • Inform genomics

  • Inserm Transfer

  • Merrimack pharmaceutical

  • USB markers

  • CombiMatrix

  • Epizyma

  • Genzyme

  • Diagnosis of exosomes

  • OrigiMed

  • Q BioMed

  • Informed data systems

  • NeuroMetrix

  • Pure MHC

  • Epitomics

  • IMIDomics

  • Astrimmune

  • Multi-immune

  • Biogenic

  • Qiagen

  • QIAGEN Translational Medicine Center (Suzhou)

  • Fusion antibody

  • Aushon BioSystems

  • Shuwen Biotech

  • German Cancer Research Center

  • Becton Dickinson

  • German Federal Ministry of Education and Research

  • London genetics

  • Golden helix

  • Gibson Oncology

  • Dalton Pharmaceutical Services

For more information on this report visit

See the source version on

Laura Wood, Senior Press Director
[email protected]
For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

Source link

Comments are closed.